TY - JOUR T1 - Response to e-letter: ‘Tocilizumab in patients with adult-onset Still’s disease refractory to glucocorticoid treatment’ by Lee JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis DO - 10.1136/annrheumdis-2018-214653 SP - annrheumdis-2018-214653 AU - Yuko Kaneko AU - Hideto Kameda AU - Kei Ikeda AU - Tomonori Ishii AU - Kosaku Murakami AU - Hyota Takamatsu AU - Yoshiya Tanaka AU - Takayuki Abe AU - Tsutomu Takeuchi Y1 - 2018/11/10 UR - http://ard.bmj.com/content/early/2018/11/10/annrheumdis-2018-214653.abstract N2 - We would like to thank Dr Lee1 for his interest in our paper2 and for his comments providing futuristic insights into the management of adult-onset Still's disease. As he highlights, conventional disease-modifying antirheumatic drugs (DMARDs) are important options for this disease.3–5 Although the safety of biological agents including tocilizumab have … ER -